Rahman A
Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40-50 Tottenham Street, W1T 4NJ, UK.
Rheumatology (Oxford). 2004 Nov;43(11):1326-36. doi: 10.1093/rheumatology/keh354. Epub 2004 Aug 24.
Anti-double-stranded DNA antibodies (anti-dsDNA) and antiphospholipid antibodies (APL) are important in the pathogenesis of systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS) respectively. Not all anti-dsDNA or APL antibodies can cause clinical effects. Those that are particularly likely to cause tissue damage tend to be of IgG isotype and to possess particular binding properties. Rigorous statistical analysis of published sequences of human monoclonal anti-DNA and APL antibodies showed that IgG antibodies with binding properties characteristic of pathogenicity tend to have multiple somatic mutations in their variable regions. The distribution of these mutations suggests that they have been selected by antigen. This leads to accumulation of certain residues at the antigen-binding sites of these antibodies. Arginine residues are especially important. A computer-generated model of the pathogenic human monoclonal anti-DNA antibody B3 predicted that arginines in the heavy and light chain complementarity-determining regions (CDRs) would interact with dsDNA. We expressed cloned sequences encoding the B3 heavy and light chains in vitro to produce whole IgG. The cloned sequences of the heavy and light chains were manipulated to express a range of variant IgG antibodies. Binding assays on the expressed antibodies showed that altering specific arginine residues reduced binding to dsDNA in a way consistent with computer generated structural models. Changing the pattern of somatic mutations in the light chain altered binding to both dsDNA and histones, but in different ways. A single arginine-to-serine mutation in light-chain CDR1 of B3 reduced binding to both those antigens and may also have reduced the pathogenicity of the expressed antibodies in severe combined immunodeficiency (SCID) mice. Monoclonal human APL were expressed using the same system. Nineteen different heavy-light combinations were expressed. The ability to bind cardiolipin correlated well with the presence of exposed arginine residues in the heavy- and light-chain CDRs. The heavy chain of the pathogenic APL antibody IS4 contains four exposed arginines in CDR3. The results of mutagenesis studies suggested that two of these promote binding to cardiolipin whereas the other two have no such effect.
抗双链DNA抗体(抗dsDNA)和抗磷脂抗体(APL)分别在系统性红斑狼疮(SLE)和抗磷脂综合征(APS)的发病机制中起重要作用。并非所有抗dsDNA或APL抗体都会产生临床效应。那些特别容易导致组织损伤的抗体往往是IgG同种型,并具有特定的结合特性。对已发表的人单克隆抗DNA和APL抗体序列进行的严格统计分析表明,具有致病性结合特性的IgG抗体在其可变区往往有多个体细胞突变。这些突变的分布表明它们是由抗原选择的。这导致这些抗体的抗原结合位点积累了某些残基。精氨酸残基尤为重要。对致病性人单克隆抗DNA抗体B3的计算机生成模型预测,重链和轻链互补决定区(CDR)中的精氨酸将与dsDNA相互作用。我们在体外表达编码B3重链和轻链的克隆序列以产生完整的IgG。对重链和轻链的克隆序列进行操作以表达一系列变体IgG抗体。对表达抗体的结合试验表明,改变特定的精氨酸残基会以与计算机生成的结构模型一致的方式降低与dsDNA的结合。改变轻链中的体细胞突变模式会以不同方式改变与dsDNA和组蛋白的结合。B3轻链CDR1中的单个精氨酸到丝氨酸突变降低了与这两种抗原的结合,并且可能也降低了在严重联合免疫缺陷(SCID)小鼠中表达抗体的致病性。使用相同系统表达人单克隆APL。表达了19种不同的重链 - 轻链组合。与心磷脂结合的能力与重链和轻链CDR中暴露的精氨酸残基的存在密切相关。致病性APL抗体IS4的重链在CDR3中含有四个暴露的精氨酸。诱变研究结果表明,其中两个促进与心磷脂的结合,而另外两个则没有这种作用。